Last reviewed · How we verify

Rectal acetaminophen

Aultman Health Foundation · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Rectal acetaminophen is a Small molecule drug developed by Aultman Health Foundation. It is currently FDA-approved.

Rectal acetaminophen is a small molecule used as an intervention in clinical trials for various conditions, including pain and colorectal cancer. It has been studied in combination with free-opioid anesthesia for analgesic efficacy in patients undergoing colorectal surgery.

At a glance

Generic nameRectal acetaminophen
SponsorAultman Health Foundation
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Rectal acetaminophen

What is Rectal acetaminophen?

Rectal acetaminophen is a Small molecule drug developed by Aultman Health Foundation.

Who makes Rectal acetaminophen?

Rectal acetaminophen is developed and marketed by Aultman Health Foundation (see full Aultman Health Foundation pipeline at /company/aultman-health-foundation).

What development phase is Rectal acetaminophen in?

Rectal acetaminophen is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing